GLP-1 receptor agonists like liraglutide are emerging as a pharmacotherapy option to counteract antidepressant-induced weight gain, alongside weight-neutral antidepressant alternatives and behavioral interventions.
GLP-1 drugs as a solutionGLP-1 receptor agonists like liraglutide are emerging as pharmacotherapy options to counteract the significant weight gain caused by many antidepressant medications
What the researchers found
Antidepressant-related weight gain is a common and clinically significant problem that can worsen metabolic health in patients already at elevated risk due to depression. The review identifies several strategies to manage this:
1. **Weight-neutral alternatives**: Bupropion, fluoxetine, and the newer agent gepirone can treat depression without the weight gain associated with many other antidepressants.
2. **Genetic prediction**: Metabolizer phenotypes and inflammation markers may help predict which patients are most susceptible to weight gain on specific antidepressants.
3. **GLP-1 receptor agonists**: Liraglutide and metformin are discussed as pharmacotherapy options to counteract antidepressant-induced weight gain.
4. **Integrated behavioral interventions**: Combining lifestyle modifications with medication management can help offset metabolic risks.
Why it matters
Depression and obesity frequently co-occur and worsen each other. The antidepressants used to treat depression often cause significant weight gain, creating a cruel clinical paradox. GLP-1 agonists like liraglutide are increasingly being considered as part of the solution — treating the weight gain that antidepressants cause while potentially also helping with depression symptoms. This intersection of psychiatric and metabolic treatment is becoming a major clinical frontier.
The numbers in context
Weight-neutral options: bupropion, fluoxetine, gepirone · Pharmacotherapy for weight gain: GLP-1 agonists (liraglutide), metformin · Genetic factors: metabolizer phenotypes, inflammation · Depression increases metabolic risk independently
How the study worked
This is a narrative review examining recent research on the relationship between antidepressant use and weight change. The authors surveyed evidence on genetic predictors of susceptibility, weight-neutral antidepressant alternatives, and pharmacological and behavioral interventions for managing antidepressant-related weight gain.
Who was studied
Review covering adults with depression at risk of antidepressant-related weight gain
What this study cannot tell us
As a narrative review, it doesn't systematically quantify the weight gain associated with each antidepressant or the efficacy of GLP-1 agonists specifically for antidepressant-induced weight gain. The use of GLP-1 agonists in this context is relatively new and evidence is still accumulating. Individual responses to antidepressants and weight management strategies vary widely.
How to read the evidence
This is a narrative review in a respected obesity journal. It synthesizes current evidence on antidepressant-weight relationships and management strategies, but the specific use of GLP-1 agonists for antidepressant-induced weight gain is an emerging area with limited controlled trial data.
When this study was published
Published in 2025, this is a current review reflecting the latest thinking on antidepressant metabolic effects. The inclusion of GLP-1 agonists as a management strategy is timely given the explosive growth of these drugs in clinical practice.
The bigger picture
The convergence of psychiatric and metabolic medicine is one of the most important trends in healthcare. GLP-1 agonists are increasingly recognized as useful not just for diabetes and obesity, but for managing the metabolic consequences of psychiatric medications. As evidence grows for GLP-1 effects on brain reward circuits, mood, and compulsive behaviors, these peptide drugs may eventually play a direct role in treating depression itself — not just its metabolic side effects.
Questions still open
- Will GLP-1 agonists be formally studied in randomized trials specifically for antidepressant-induced weight gain?
- Could GLP-1 drugs' emerging effects on brain reward circuits provide direct antidepressant benefits alongside weight management?
- How should clinicians weigh the cost and injectable burden of GLP-1 agonists against switching to a weight-neutral antidepressant?
Common questions
Why do antidepressants cause weight gain?
Can GLP-1 drugs help with weight gain from antidepressants?
Read the original research
Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications.
Current obesity reports, 14(1), 2
Citation
Moss, Lauren; Laudenslager, Marci; Steffen, Kristine J; Sockalingam, Sanjeev; Coughlin, Janelle W. (2025). Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications.. Current obesity reports, 14(1), 2. https://doi.org/10.1007/s13679-024-00598-5